A protein once thought to affect only Parkinson's disease is now revealing itself as a major player in dementia diagnosis, appearing in roughly 60% of people with neurodegenerative disease. This discovery is forcing neurologists to abandon symptom-based diagnosis and move toward identifying the actual biological changes happening in the brain, a shift that could dramatically improve treatment outcomes.

Why Symptom-Based Diagnosis Is Failing Patients?

For decades, neurologists diagnosed dementia the same way: by watching for memory loss, tremors, hallucinations, and other visible signs. The problem is that these symptoms overlap dramatically across different diseases. Parkinson's disease, Lewy body dementia, Alzheimer's disease, and multiple system atrophy can look nearly identical in their early stages, leading to misdiagnosis rates as low as 3 to 6% accuracy for certain subtypes.

Rebecca Chopp, former chancellor of the University of Denver, experienced this firsthand. After her neurologist diagnosed her with mild cognitive impairment due to Alzheimer's disease in 2019, she stepped down from her position, convinced she had only a few years of cognitive function left. "In three years, you won't be able to button your shirt," her neurologist had warned. Six years later, after undergoing newer blood tests that detect biological markers of Alzheimer's, Chopp discovered she had no amyloid or tau buildup in her brain at all. Her symptoms had been caused by stress, poor sleep, and a small brain injury unrelated to Alzheimer's.

The reality is that most neurodegenerative diseases are driven by misfolded proteins that spread through the brain in distinct patterns. A patient might have amyloid plaques, tau tangles, and alpha-synuclein aggregates all at the same time, a biological complexity that clinical observation alone cannot untangle.

What Is Alpha-Synuclein and Why Does It Matter?

Alpha-synuclein is a protein that normally serves important functions in the brain. In synucleinopathies, a major class of neurodegenerative disease, this protein misfolds and clumps together inside neurons, forming structures called Lewy bodies and Lewy neurites that disrupt communication between brain cells and eventually cause cell death.

For years, researchers assumed alpha-synuclein would be relevant in only about 25% of dementia cases. New evidence suggests the reality is far more widespread. "Initially, we assumed synuclein would be relevant in maybe a quarter of patients," explained Russell Lebovitz, CEO of Amprion Diagnostics. "What we've learned since is that it shows up in closer to 60 percent of people with neurodegenerative disease".

The protein's influence extends beyond the diseases it directly causes. Experimental evidence suggests that misfolded alpha-synuclein can interact with and potentially accelerate the aggregation of amyloid-beta and tau, the two hallmark proteins of Alzheimer's disease. Rather than existing in isolation, these misfolded proteins appear increasingly interconnected, contributing to a broader and more complex neurodegenerative cascade.

How Different Types of Dementia Present Differently?

Understanding the specific proteins involved in each dementia type is crucial because they produce distinct symptoms and require different approaches to treatment. Lewy body dementia, the second most common neurodegenerative form of dementia, is caused by alpha-synuclein misfolding. Unlike Alzheimer's disease, which primarily affects short-term memory, Lewy body dementia often presents with vivid visual hallucinations early on, even when cognitive impairment is mild.

People with Lewy body dementia also experience movement problems characteristic of Parkinson's disease, including slowness of movement, tremors at rest, and balance difficulties. Another distinctive feature is REM Sleep Behavior Disorder, where people act out their dreams by yelling, punching, kicking, or jumping out of bed.

Vascular dementia, the second most common overall cause of dementia, results from damage to the brain's blood vessels. It can appear suddenly after a stroke or develop gradually over time as blood vessels harden. Frontotemporal dementia, which can strike people younger than 65, causes dramatic personality changes and language difficulties because it affects the frontal and temporal lobes.

How to Get an Accurate Dementia Diagnosis Today?

• Cognitive Screening Tests: Doctors use standardized assessments like the Montreal Cognitive Assessment (MoCA) or Mini-Mental State Examination (MMSE) to evaluate memory, attention, language, and reasoning. These tests help determine whether further investigation is needed but cannot diagnose Alzheimer's on their own.
• Brain Imaging: MRI scans reveal shrinkage in specific brain regions, particularly the hippocampus, which is most affected in early Alzheimer's. PET scans can detect abnormal deposits of amyloid or tau protein before structural changes become visible.
• Blood-Based Biomarker Tests: The most significant recent advance is blood tests that detect plasma amyloid-beta and tau peptide, proteins that reflect changes occurring in the brain. These tests are increasingly accessible and can support earlier diagnosis without requiring spinal fluid or brain imaging.
• Neurological Examination: A complete neurological exam evaluates reflexes, coordination, muscle tone, eye movement, speech, and balance to identify conditions other than Alzheimer's that may be causing cognitive symptoms.
• Routine Blood Work: Standard blood tests rule out treatable conditions that can mimic dementia, including thyroid dysfunction, vitamin B12 deficiency, diabetes, and infections.

The key difference between old and new diagnostic approaches is that modern testing identifies the actual biological changes in the brain rather than relying solely on symptoms. Chopp's experience illustrates this shift. When she was initially diagnosed six years ago, blood biomarker tests did not exist. When she underwent testing with a new neurologist, the blood test revealed no amyloid or tau buildup, and her cognitive test scores were dramatically different from her initial assessment.

Why Early Detection Matters More Than Ever?

Early diagnosis carries significant value because neurodegenerative diseases begin changing the brain long before symptoms appear. By the time memory difficulties become noticeable, the disease has often been developing quietly for years. When Alzheimer's is identified in its earlier stages, treatment can begin sooner, which may help slow symptom progression and preserve independence longer.

Early assessment also identifies other conditions that mimic dementia symptoms, such as thyroid disorders, vitamin B12 deficiency, depression, or medication side effects. Many of these are entirely treatable. Catching them early means they can be addressed before they cause lasting harm.

Dr. Stuart McCarter, senior associate consultant in Mayo Clinic's Department of Neurology, emphasizes that dementia is not a single disease but an umbrella term for symptoms of memory loss. "Anything that interferes with your brain's ability to do what it's supposed to do could lead to mild cognitive impairment or dementia," he explained. "All of these things have different treatments. Some are reversible, and they also have different prognostic implications".

The shift toward biological diagnosis represents a fundamental change in how neurologists approach dementia. Rather than waiting for symptoms to worsen or relying on clinical presentation alone, doctors can now identify the specific proteins driving cognitive decline and tailor treatment accordingly. For patients like Rebecca Chopp, this advancement means the difference between a devastating diagnosis and discovering that lifestyle changes and stress reduction can restore cognitive function. For the millions of people at risk of dementia, it means earlier intervention, more accurate diagnosis, and better chances of preserving independence.